The Design of Nested Adaptive Clinical Trials of Multiple Organ Dysfunction Syndrome Children in a Single Study.

John M VanBuren, Mark Hall, Athena F Zuppa, Peter M Mourani, Joseph Carcillo, J Michael Dean, Kevin Watt, Richard Holubkov

December 2023

Synopsis of Social media discussions

The discussions reveal a strong interest in the innovative trial approaches and personalized treatments presented in the article, with mentions of the potential for improving outcomes in pediatric sepsis. Words like 'possibilities' and references to podcasts suggest a positive tone and curiosity about the research's implications, emphasizing its relevance and potential transformative impact in the field.

A
Agreement
 Moderate agreement

The discussions reflect general support for the importance of personalized immunomodulation and innovative trial designs, indicating agreement with the publication's approach.

I
Interest
 High level of interest

Participants show high interest by engaging with topics like immunology, inflammation, and personalized treatments, demonstrated through enthusiastic language.

E
Engagement
 Moderate level of engagement

Comments include praise and references to podcasts discussing the research, suggesting a moderate level of in-depth engagement.

I
Impact
 Moderate level of impact

The discussions highlight the potential significance of adaptive trial designs and personalized treatments in pediatric intensive care, indicating a moderate impact.

Social Mentions

YouTube

1 Videos

Twitter

4 Posts

Metrics

Video Views

1,908

Total Likes

37

Extended Reach

31,267

Social Features

5

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Personalized Immunotherapy Approaches for Critically Ill Children with Sepsis

Personalized Immunotherapy Approaches for Critically Ill Children with Sepsis

Dr. Mark Hall discusses immunology and inflammation in pediatric sepsis treatment using immune phenotyping to personalize treatment. The talk covers the history of inflammatory responses, distinguishes between proinflammatory and immune paralysis, and explores adaptive clinical trials like PRECISE, GRACE2, and TRIPS for tar

OPENPediatrics

November 27, 2023

1,908 views

  • Kerri LaRovere MD, MMSc
    @KerriLarovere (Twitter)

    RT @OPENPediatrics: Our Physician World Shared Practice Forum podcast is here. Listen as Dr. Mark Hall discusses immunology, inflammation,…
    view full post

    December 1, 2023

    2

  • Jeffrey Burns, MD
    @burns_md (Twitter)

    RT @OPENPediatrics: Our Physician World Shared Practice Forum podcast is here. Listen as Dr. Mark Hall discusses immunology, inflammation,…
    view full post

    December 1, 2023

    2

  • OPENPediatrics
    @OPENPediatrics (Twitter)

    Our Physician World Shared Practice Forum podcast is here. Listen as Dr. Mark Hall discusses immunology, inflammation, and the possibilities of personalized treatments in pediatric sepsis. https://t.co/5vCN0k7PGP #PedsICU #PedsSepsis #MedEd
    view full post

    December 1, 2023

    6

    2

  • OPENPediatrics
    @OPENPediatrics (Twitter)

    Our Physician World Shared Practice Forum podcast is here. Listen as Dr. Mark Hall discusses immunology, inflammation, and the possibilities of personalized treatments in pediatric sepsis. https://t.co/5vCN0k7PGP #PedsICU #PedsSepsis #MedEd
    view full post

    November 28, 2023

    4

Abstract Synopsis

  • It includes two main study arms: the GRACE2 trial, testing GMCSF to reverse immunoparalysis, and the TRIPS trial, testing different doses of anakinra to reduce systemic inflammation, both utilizing adaptive statistical frameworks for early stopping based on efficacy or futility.
  • The trials are conducted across 24 US pediatric intensive care units (PICUs) and measure outcomes mainly through the pediatric logistic organ dysfunction (PELOD) score over 28 days, with data analysis employing non-parametric tests like the Wilcoxon Rank Sum to compare treatment effects.]